Diseases Industry Analysis
Reportbuyer.com helps you stay ahead with advanced reports on Diseases. Information includes Competitive Positioning, Stakeholder Opinions and Future Market Watch.
previous
| Global Hepatitis C Drugs Market (INF01684) 2011-2015TechNavio's analysts forecast the Global Hepatitis C Drugs market to grow at a CAGR of 28 percent over the period 2011-2015. One of the key factors contributing to this market... | May 2012 | £945 |
| Global Trauma Market Report (KOA04970) 2012 EditionThe worldwide trauma market has experienced significant growth in the past and the market has considerable growth opportunity in the near future as the worldwide demand for trauma products is... | May 2012 | £505 |
| Triple Analysis: Melanoma, Protein Kinase Inhibitors and Peptides (BSK00447) This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Melanoma), one mechanism/target/effect area (Protein Kinase Inhibitors) and one compound specific area (Peptides). Each of these... | May 2012 | £2,845 |
| Triple Analysis: Lymphoma, Melanoma and Protein Kinase Inhibitors (BSK00390) This triple analysis focuses on cancer drug development strategies in both Lymphoma and Melanoma and by the mechanism/target/effect of Protein Kinase Inhibitors. Each of these three individual parts is evaluated... | May 2012 | £2,845 |
| Triple Analysis: Leukemia, Melanoma and Protein Kinase Inhibitors (BSK00309) This triple analysis focuses on cancer drug development strategies in both Leukemia and Melanoma and by the mechanism/target/effect of Protein Kinase Inhibitors. Each of these three individual parts is evaluated... | May 2012 | £2,845 |
| Triple Analysis: Melanoma, Protein Kinase Inhibitors and Antibodies (BSK00446) This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Melanoma), one mechanism/target/effect area (Protein Kinase Inhibitors) and one compound specific area (Antibodies). Each of these... | May 2012 | £2,845 |
| Triple Analysis: Protein Kinase Inhibitors, Antibodies and Peptides (BSK00504) This triple analysis focuses on cancer drug development strategies by the mechanism/target/effect of Protein Kinase Inhibitors and by the two compound strategies of Antibodies and Peptides. Each of these three... | May 2012 | £2,845 |
| Triple Analysis: Melanoma, Apoptosis and Protein Kinase Inhibitors (BSK00436) This triple analysis focuses on cancer drug development strategies in Melanoma and by the two mechanism/target/effect areas of Apoptosis and Protein Kinase Inhibitors. Each of these three individual parts is... | May 2012 | £2,845 |
| Triple Analysis: Lymphoma, Protein Kinase Inhibitors and Peptides (BSK00419) This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Lymphoma), one mechanism/target/effect area (Protein Kinase Inhibitors) and one compound specific area (Peptides). Each of these... | May 2012 | £2,845 |
| Triple Analysis: Melanoma, Angiogenesis and Protein Kinase Inhibitors (BSK00440) This triple analysis focuses on cancer drug development strategies in Melanoma and by the two mechanism/target/effect areas of Angiogenesis and Protein Kinase Inhibitors. Each of these three individual parts is... | May 2012 | £2,845 |
| Triple Analysis: Leukemia, Protein Kinase Inhibitors and Peptides (BSK00338) This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Leukemia), one mechanism/target/effect area (Protein Kinase Inhibitors) and one compound specific area (Peptides). Each of these... | May 2012 | £2,845 |
| Triple Analysis: Leukemia, Lymphoma and Protein Kinase Inhibitors (BSK00301) This triple analysis focuses on cancer drug development strategies in both Leukemia and Lymphoma and by the mechanism/target/effect of Protein Kinase Inhibitors. Each of these three individual parts is evaluated... | May 2012 | £2,845 |
| Triple Analysis: Lymphoma, Protein Kinase Inhibitors and Antibodies (BSK00418) This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Lymphoma), one mechanism/target/effect area (Protein Kinase Inhibitors) and one compound specific area (Antibodies). Each of these... | May 2012 | £2,845 |
| Triple Analysis: Apoptosis, Protein Kinase Inhibitors and Peptides (BSK00493) This triple analysis focuses on cancer drug development strategies by the two mechanism/target/effect areas of Apoptosis and Protein Kinase Inhibitors and by the compound strategy of Peptides. Each of these... | May 2012 | £2,845 |
| Triple Analysis: Leukemia, Protein Kinase Inhibitors and Antibodies (BSK00337) This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Leukemia), one mechanism/target/effect area (Protein Kinase Inhibitors) and one compound specific area (Antibodies). Each of these... | May 2012 | £2,845 |
| Triple Analysis: Angiogenesis, Protein Kinase Inhibitors and Peptides (BSK00499) This triple analysis focuses on cancer drug development strategies by the two mechanism/target/effect areas of Angiogenesis and Protein Kinase Inhibitors and by the compound strategy of Peptides. Each of these... | May 2012 | £2,845 |
| Triple Analysis: Lymphoma, Apoptosis and Protein Kinase Inhibitors (BSK00408) This triple analysis focuses on cancer drug development strategies in Lymphoma and by the two mechanism/target/effect areas of Apoptosis and Protein Kinase Inhibitors. Each of these three individual parts is... | May 2012 | £2,845 |
| Triple Analysis: Leukemia, Apoptosis and Protein Kinase Inhibitors (BSK00327) This triple analysis focuses on cancer drug development strategies in Leukemia and by the two mechanism/target/effect areas of Apoptosis and Protein Kinase Inhibitors. Each of these three individual parts is... | May 2012 | £2,845 |
| Triple Analysis: Lymphoma, Angiogenesis and Protein Kinase Inhibitors (BSK00412) This triple analysis focuses on cancer drug development strategies in Lymphoma and by the two mechanism/target/effect areas of Angiogenesis and Protein Kinase Inhibitors. Each of these three individual parts is... | May 2012 | £2,845 |
| Triple Analysis: Apoptosis, Protein Kinase Inhibitors and Antibodies (BSK00492) This triple analysis focuses on cancer drug development strategies by the two mechanism/target/effect areas of Apoptosis and Protein Kinase Inhibitors and by the compound strategy of Antibodies. Each of these... | May 2012 | £2,845 |
| Triple Analysis: Leukemia, Angiogenesis and Protein Kinase Inhibitors (BSK00331) This triple analysis focuses on cancer drug development strategies in Leukemia and by the two mechanism/target/effect areas of Angiogenesis and Protein Kinase Inhibitors. Each of these three individual parts is... | May 2012 | £2,845 |
| Triple Analysis: Angiogenesis, Protein Kinase Inhibitors and Antibodies (BSK00498) This triple analysis focuses on cancer drug development strategies by the two mechanism/target/effect areas of Angiogenesis and Protein Kinase Inhibitors and by the compound strategy of Antibodies. Each of these... | May 2012 | £2,845 |
| Triple Analysis: Apoptosis, Angiogenesis and Protein Kinase Inhibitors (BSK00486) This triple analysis focuses on cancer drug development strategies by mechanism/target/effect of Apoptosis, Angiogenesis and Protein Kinase Inhibitors. Each of these three individual parts is evaluated according to standardized criteria... | May 2012 | £2,845 |
| Triple Analysis: Melanoma, Prostate Cancer and Protein Kinase Inhibitors (BSK00431) This triple analysis focuses on cancer drug development strategies in both Melanoma and Prostate Cancer and by the mechanism/target/effect of Protein Kinase Inhibitors. Each of these three individual parts is... | May 2012 | £2,845 |
| Triple Analysis: Melanoma, Pancreatic Cancer and Protein Kinase Inhibitors (BSK00425) This triple analysis focuses on cancer drug development strategies in both Melanoma and Pancreatic Cancer and by the mechanism/target/effect of Protein Kinase Inhibitors. Each of these three individual parts is... | May 2012 | £2,845 |
